NasdaqGM - Nasdaq Real Time Price USD

EyePoint Pharmaceuticals, Inc. (EYPT)

8.93
-0.01
(-0.11%)
At close: June 9 at 4:00:01 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
56,042
43,273
46,018
41,404
36,939
Cost of Revenue
3,758
3,712
4,632
8,326
8,177
Gross Profit
52,284
39,561
41,386
33,078
28,762
Operating Expense
213,654
185,415
116,453
112,016
84,038
Operating Income
-161,370
-145,854
-75,067
-78,938
-55,276
Net Non Operating Interest Income Expense
14,679
15,074
5,702
-1,058
-5,206
Other Income Expense
--
--
-1,347
-22,258
2,065
Pretax Income
-146,691
-130,780
-70,712
-102,254
-58,417
Tax Provision
--
90
83
0
--
Net Income Common Stockholders
-146,781
-130,870
-70,795
-102,254
-58,417
Diluted NI Available to Com Stockholders
-146,781
-130,870
-70,795
-102,254
-58,417
Basic EPS
-2.42
--
-1.82
-2.74
-2.03
Diluted EPS
-2.42
--
-1.82
-2.74
-2.03
Basic Average Shares
60,511.50
--
38,904
37,317
28,758
Diluted Average Shares
60,511.50
--
38,904
37,317
28,758
Total Operating Income as Reported
-161,370
-145,854
-75,067
-99,637
-55,276
Total Expenses
217,412
189,127
121,085
120,342
92,215
Net Income from Continuing & Discontinued Operation
-146,781
-130,870
-70,795
-102,254
-58,417
Normalized Income
-146,781
-130,870
-69,730.87
-79,996
-60,482
Interest Income
14,693
15,088
6,949
2,131
292
Interest Expense
--
14
1,247
3,189
5,498
Net Interest Income
14,679
15,074
5,702
-1,058
-5,206
EBIT
-146,282
-130,766
-69,465
-99,065
-52,919
EBITDA
-144,548
-129,226
-69,001
-96,619
-50,148
Reconciled Cost of Revenue
3,758
3,712
4,632
7,930
7,866
Reconciled Depreciation
1,734
1,540
464
2,446
2,771
Net Income from Continuing Operation Net Minority Interest
-146,781
-130,870
-70,795
-102,254
-58,417
Total Unusual Items Excluding Goodwill
0
0
-1,347
-22,258
2,065
Total Unusual Items
0
0
-1,347
-22,258
2,065
Normalized EBITDA
-144,548
-129,226
-67,654
-74,361
-52,213
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
-282.87
0
0
12/31/2021 - 1/27/2005

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OCUL Ocular Therapeutix, Inc.
8.90
-1.33%
 
FDMT 4D Molecular Therapeutics, Inc.
4.7900
+10.11%
 
KOD Kodiak Sciences Inc.
4.1500
-1.66%
 
CLSD Clearside Biomedical, Inc.
0.7610
-3.24%
 
GLUE Monte Rosa Therapeutics, Inc.
4.9200
-1.80%
 
RGNX REGENXBIO Inc.
9.53
-0.83%
 
ETNB 89bio, Inc.
10.57
+3.12%
 
ATXS Astria Therapeutics, Inc.
5.79
-3.34%
 
VRDN Viridian Therapeutics, Inc.
14.86
+1.23%
 
RCUS Arcus Biosciences, Inc.
9.85
-1.20%